The advent of novel, second-generation anti-obesity medications, from currently approved glucagon-like peptide 1 receptor agonists (GLP-1RAs) to new agents in the pipeline, now provide powerful tools for the management of adiposity-based chronic diseases. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.